Formulation comprising metformin and vildagli ptin

Details for Australian Patent Application No. 2006297444 (hide)

Owner Novartis AG

Inventors Tong, Wei-Qin; Joshi, Yatindra; Vasanthavada, Madhav; Kowalski, James; Lakshman, Jay Parthiban; Royce, Alan Edward

Agent Davies Collison Cave

Pub. Number AU-B-2006297444

PCT Pub. Number WO2007/041053

Priority 60/722,624 29.09.05 US

Filing date 25 September 2006

Wipo publication date 12 April 2007

Acceptance publication date 12 August 2010

International Classifications

A61K 31/155 (2006.01) - Amidines (), e.g. guanidine (HNC(NH)NH), isourea (HNC(OH)NH), isothiourea (HNC(SH)NH)

A61K 9/20 (2006.01) Medicinal preparations characterised by special physical form - Pills, lozenges or tablets

A61K 9/48 (2006.01) Medicinal preparations characterised by special physical form - Preparations in capsules, e.g. of gelatin, of chocolate

A61K 31/40 (2006.01) - having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

A61K 31/4439 (2006.01)

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

Event Publications

10 April 2008 PCT application entered the National Phase

  PCT publication WO2007/041053 Priority application(s): WO2007/041053

12 August 2010 Application Accepted

  Published as AU-B-2006297444

9 December 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006297452-Acylated piperidine derivatives as melanocortin-4 receptor agonists

2006297443-Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators